Matthew Ulrickson, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Miltenyi
    Topic:
    zamtocabtagene
    Date added:
    07/18/2023
    Date updated:
    07/18/2023
    Relationship end date:
    06/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Gilead
    Topic:
    MDS
    Date added:
    07/18/2023
    Date updated:
    07/18/2023
    Relationship end date:
    03/04/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Bristol Meyers Squib
    Topic:
    AML
    Date added:
    07/18/2023
    Date updated:
    07/18/2023
    Relationship end date:
    02/11/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Stemline
    Topic:
    BPDCN
    Date added:
    07/18/2023
    Date updated:
    07/18/2023
    Relationship end date:
    07/30/2021
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Genetech
    Topic:
    AML
    Date added:
    07/18/2023
    Date updated:
    07/18/2023
    Relationship end date:
    05/27/2023
Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes